MedDataX Logo

A Study in Healthy People to Test How 2 Different Formulations of BI 690517 Are Taken up in the Body and How Probenecid Influences the Amount of BI 690517 in the Blood

NCT ID: NCT06647810

Last Updated: 2025-01-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-11-13

Study Completion Date

2025-01-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial aims to test how two different formulations of BI 690517 are taken up by the body and how probenecid influences the amount of BI 690517 in the blood.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study in Healthy People to Test How 2 Different Doses of BI 1291583 Are Taken up in the Body When Given in 3 Different Formulations

NCT06631417

Healthy
COMPLETED PHASE1

A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435

NCT01209117

Infections, Human Immunodeficiency Virus and Herpesviridae Infection, Human Immunodeficiency Virus
COMPLETED PHASE1

This Study Tests How Different Doses of BI 690517 Are Taken up in the Body of Healthy Men. The Study Also Looks at How Food Influences the Amount of BI 690517 in the Blood

NCT03100916

Healthy
COMPLETED PHASE1

A Study to Investigate the Recovery, Excretion and Pharmacokinetics of [14C]-GSK2140944 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects

NCT02000765

Infections, Respiratory Tract
COMPLETED PHASE1

A Study in Healthy Men to Test How BI 690517 is Taken up and Handled by the Body

NCT05515588

Healthy
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BI 690517 formulation 1, then BI 690517 formulation 2, then Probenecid + BI 690517 formulation 2

Group Type EXPERIMENTAL

BI 690517 formulation 1

Intervention Type DRUG

BI 690517 formulation 1

BI 690517 formulation 2

Intervention Type DRUG

BI 690517 formulation 2

Probenecid

Intervention Type DRUG

Probenecid

BI 690517 formulation 2, then Probenecid + BI 690517 formulation 2, then BI 690517 formulation 1

Group Type EXPERIMENTAL

BI 690517 formulation 1

Intervention Type DRUG

BI 690517 formulation 1

BI 690517 formulation 2

Intervention Type DRUG

BI 690517 formulation 2

Probenecid

Intervention Type DRUG

Probenecid

Probenecid + BI 690517 formulation 2, then BI 690517 formulation 1, then BI 690517 formulation 2

Group Type EXPERIMENTAL

BI 690517 formulation 1

Intervention Type DRUG

BI 690517 formulation 1

BI 690517 formulation 2

Intervention Type DRUG

BI 690517 formulation 2

Probenecid

Intervention Type DRUG

Probenecid

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BI 690517 formulation 1

BI 690517 formulation 1

Intervention Type DRUG

BI 690517 formulation 2

BI 690517 formulation 2

Intervention Type DRUG

Probenecid

Probenecid

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Vicadrostat Vicadrostat Probenecid Biokanol®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy male or female subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), and clinical laboratory tests
* Age of 18 to 55 years (inclusive)
* Body mass index (BMI) of 18.5 to 29.9 kg/m² (inclusive)

Exclusion Criteria

* Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator
* Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 bpm (beats per minute)
* Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Humanpharmakologisches Zentrum Biberach

Biberach, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Related Links

Access external resources that provide additional context or updates about the study.

https://www.mystudywindow.com

Related Info

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2024-513590-45-00

Identifier Type: REGISTRY

Identifier Source: secondary_id

U1111-1307-2145

Identifier Type: REGISTRY

Identifier Source: secondary_id

1378-0025

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Bioavailability of 3 Different Formulations of BI 207127 in Healthy Male Volunteers
NCT01535638 COMPLETED PHASE1
Clinical Drug Trial in Healthy Male Subjects to Determine and Compare the Blood Concentrations of BI 144807 Following Administration as Oral Solution and Tablet Under Fasted and Fed Conditions
NCT01897597 COMPLETED PHASE1
Effect of Probenecid on Pexidartinib Pharmacokinetics
NCT03138759 COMPLETED PHASE1
Comparative Bioavailability Study of Clarithromycin 500 mg Tablets in Fasting State
NCT00648960 COMPLETED PHASE1
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
NCT05515328 COMPLETED PHASE1
A Study to Test How BI 1819479 is Taken up and Processed by the Body
NCT07065617 TERMINATED PHASE1
A Study in Healthy Men and Women to Test How BI 3000202 is Taken up and Processed by the Body
NCT07273474 RECRUITING PHASE1
Assess the Oral Bioavailability of a New ABT-263 Formulation in Healthy Female Subjects
NCT01053520 COMPLETED PHASE1
To Demonstrate the Relative Bioavailability of Azithromycin 600 mg Tablets Under Fed Conditions
NCT00865670 COMPLETED PHASE1
Safety, Tolerability, and Pharmacokinetics of a Subcutaneous and Intravenous Dose of BI 655130 in Healthy Subjects
NCT03100903 COMPLETED PHASE1
A Bioavailability and Pharmacokinetic Study of Subcutaneous and Intravenous RO6811135 in Healthy Volunteers
NCT01802853 COMPLETED PHASE1
Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy Volunteers
NCT02182414 COMPLETED PHASE1
A Study in Healthy People to Compare 2 Different Formulations of BI 1358894 Tablets Taken With or Without Food
NCT05155306 COMPLETED PHASE1
A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the Blood
NCT06070610 COMPLETED PHASE1
A Study in Healthy People to Test How 3 Different Formulations of BI 764198 Are Taken up in the Body and How This is Influenced by Food
NCT06955754 COMPLETED PHASE1
A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood
NCT03817476 COMPLETED PHASE1
A Study in Healthy People to Test How 2 Different Formulations of BI 695501 Are Taken up by the Body When Given as an Injection
NCT05203289 COMPLETED PHASE1
Relative Bioavailability of a BI 187004 Tablet Formulation in Comparison With an Oral Solution and the Influence of Food on the Tablet Formulation in Healthy Volunteers
NCT02161432 COMPLETED PHASE1
Relative Bioavailability of BI 1467335 Tablet and Oral Solution, and Food Effect on Tablet in Healthy Male Subjects
NCT02999191 COMPLETED PHASE1
Bioavailability and Pharmacokinetics of BI 135585 XX Administered as Tablet With and Without Food
NCT01286571 COMPLETED PHASE1
Comparative Bioavailability Study of 600mg Azithromycin Monohydrate Tablets Under Fasting Conditions
NCT00866216 COMPLETED PHASE1
A Study in Healthy Men to Test if Different Formulations of BI 764198 With or Without Food Influence the Amount of BI 764198 in the Blood
NCT04656288 COMPLETED PHASE1
Bioavailability of BI 1356 After Co-administration With Ritonavir Compared to the Bioavailability of BI 1356 Alone in Healthy Male Volunteers
NCT02183441 COMPLETED PHASE1
A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same Time
NCT04263350 COMPLETED PHASE1
This Study in Healthy Men and Women Tests How the Body Takes up BI 409306
NCT03505151 COMPLETED PHASE1